Nardosinone regulates the slc38a2 gene to alleviate Parkinson's symptoms in rats through the GABAergic synaptic and cAMP pathways
Copyright © 2022. Published by Elsevier Masson SAS..
In a rotenone-induced Parkinson's disease (PD) rat model, behavioral investigation, pathological examination, inflammatory factor analysis, and mitochondrial structure and function investigation verified the anti-PD efficacy of nardosinone. A combined transcriptome and proteome analysis proposed that the anti-PD target of nardosinone is the slc38a2 gene and may involve the GABAergic synaptic pathway and cAMP-signaling pathway. Analysis of targeted slc38a2 knockout cells and expression of key enzyme-encoding genes in both pathways verified the target and pathways proposed by the 'omics analysis. This further confirms that nardosinone can regulate the slc38a2 gene, a potential new target for the treatment of Parkinson's disease, and plays an anti-PD role through the GABAergic synaptic and cAMP pathways.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:153 |
|---|---|
| Enthalten in: |
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 153(2022) vom: 15. Sept., Seite 113269 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bian, Li-Hua [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
03L9OT429T |
|---|
| Anmerkungen: |
Date Completed 08.09.2022 Date Revised 08.09.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.biopha.2022.113269 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM342495372 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM342495372 | ||
| 003 | DE-627 | ||
| 005 | 20231226014240.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.biopha.2022.113269 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1141.xml |
| 035 | |a (DE-627)NLM342495372 | ||
| 035 | |a (NLM)35728354 | ||
| 035 | |a (PII)S0753-3322(22)00658-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bian, Li-Hua |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nardosinone regulates the slc38a2 gene to alleviate Parkinson's symptoms in rats through the GABAergic synaptic and cAMP pathways |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.09.2022 | ||
| 500 | |a Date Revised 08.09.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022. Published by Elsevier Masson SAS. | ||
| 520 | |a In a rotenone-induced Parkinson's disease (PD) rat model, behavioral investigation, pathological examination, inflammatory factor analysis, and mitochondrial structure and function investigation verified the anti-PD efficacy of nardosinone. A combined transcriptome and proteome analysis proposed that the anti-PD target of nardosinone is the slc38a2 gene and may involve the GABAergic synaptic pathway and cAMP-signaling pathway. Analysis of targeted slc38a2 knockout cells and expression of key enzyme-encoding genes in both pathways verified the target and pathways proposed by the 'omics analysis. This further confirms that nardosinone can regulate the slc38a2 gene, a potential new target for the treatment of Parkinson's disease, and plays an anti-PD role through the GABAergic synaptic and cAMP pathways | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a GABAergic synaptic pathway | |
| 650 | 4 | |a Nardosinone | |
| 650 | 4 | |a Parkinson’s disease | |
| 650 | 4 | |a slc38a2 | |
| 650 | 7 | |a Polycyclic Sesquiterpenes |2 NLM | |
| 650 | 7 | |a Rotenone |2 NLM | |
| 650 | 7 | |a 03L9OT429T |2 NLM | |
| 650 | 7 | |a nardosinone |2 NLM | |
| 650 | 7 | |a 23720-80-1 |2 NLM | |
| 700 | 1 | |a Yao, Zi-Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Zhe-Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xiao-Mei |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Qiu-Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Xue |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jia-Yuan |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Xiao-Jia |e verfasserin |4 aut | |
| 700 | 1 | |a Wan, Guo-Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yu-Qing |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Jin-Li |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Jian-You |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie |d 1984 |g 153(2022) vom: 15. Sept., Seite 113269 |w (DE-627)NLM012645591 |x 1950-6007 |7 nnns |
| 773 | 1 | 8 | |g volume:153 |g year:2022 |g day:15 |g month:09 |g pages:113269 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.biopha.2022.113269 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 153 |j 2022 |b 15 |c 09 |h 113269 | ||